2022年欧洲胸外科医师学会与美国胸外科医师协会联合指南:胸外科肿瘤相关静脉血栓栓塞症的预防
该联合指南由欧洲胸外科医师学会与美国胸外科医师协会制定,采用GRADE方法,针对肺癌或食管癌手术切除患者形成24条推荐。多数推荐证据确定性为低或极低, panel对胃肠外抗凝联合机械预防优于无预防、胃肠外抗凝优于直接口服抗凝药等给出条件性推荐。
要点
- 对接受解剖性肺切除或食管切除术的癌症患者,条件性推荐胃肠外抗凝联合机械方法预防VTE,优于无预防。
- 条件性推荐胃肠外抗凝优于直接口服抗凝药,直接口服抗凝药仅建议在临床试验中使用。
- 仅对血栓中或高风险患者,条件性推荐延长预防28至35天优于仅住院期间预防。
核心结论
- 多数推荐的支持证据确定性被判定为低或极低,主要因胸外科缺乏直接证据。
- panel对胃肠外抗凝联合机械方法预防VTE优于无预防给出条件性推荐。
- 其他关键推荐包括胃肠外抗凝优于直接口服抗凝药、特定患者延长预防28至35天、以及肺全切和食管切除患者的VTE筛查。
研究设计与样本
- 美国胸外科医师协会与欧洲胸外科医师学会组建多学科指南小组,采用GRADE方法制定推荐。
- 麦克马斯特大学GRADE中心支持指南制定过程,包括更新或执行系统证据评价。
- 小组就24条推荐达成共识,聚焦肺叶切除、肺段切除、肺全切、食管切除及肺癌扩大切除患者的药物和机械预防。
主要发现
- 多数推荐的支持证据确定性被判定为低或极低。
- panel对胃肠外抗凝联合机械方法优于无预防给出条件性推荐。
- 条件性推荐胃肠外抗凝优于直接口服抗凝药,直接口服抗凝药仅建议在临床试验中使用。
- 仅对血栓中或高风险患者,条件性推荐延长预防28至35天优于仅住院期间预防。
- 对肺全切和食管切除患者给出VTE筛查的条件性推荐。
关键数值与推荐
- 条件性推荐:对接受解剖性肺切除或食管切除术的癌症患者,使用胃肠外抗凝联合机械方法预防VTE,优于无预防。
- 条件性推荐:胃肠外抗凝优于直接口服抗凝药;直接口服抗凝药仅建议在临床试验中使用。
- 条件性推荐:仅对血栓中或高风险患者,延长预防28至35天优于仅住院期间预防。
- 条件性推荐:对肺全切和食管切除患者进行VTE筛查。
临床怎么用
- 原文未据此给出推荐。
局限性
- 多数推荐的支持证据确定性被判定为低或极低,主要因胸外科缺乏直接证据。
- 未来研究重点包括术前血栓预防的作用以及风险分层指导延长预防的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a potentially fatal but preventable postoperative complication. Thoracic oncology patients undergoing surgical resection, often after multimodality induction therapy, represent among the highest risk groups for postoperative VTE. Currently there are no VTE prophylaxis guidelines specific to these thoracic surgery patients. Evidenced-based recommendations will help clinicians manage and mitigate risk of VTE in the postoperative period and inform best practice. OBJECTIVE: These joint evidence-based guidelines from The American Association for Thoracic Surgery and the European Society of Thoracic Surgeons aim to inform clinicians and patients in decisions about prophylaxis to prevent VTE in patients undergoing surgical resection for lung or esophageal cancer. METHODS: The American Association for Thoracic Surgery and the European Society of Thoracic Surgeons formed a multidisciplinary guideline panel that included broad membership to minimize potential bias when formulating recommendations. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used, including GRADE Evidence-to-Decision frameworks, which were subject to public comment. RESULTS: The panel agreed on 24 recommendations focused on pharmacological and mechanical methods for prophylaxis in patients undergoing lobectomy and segmentectomy, pneumonectomy, and esophagectomy, as well as extended resections for lung cancer. CONCLUSIONS: The certainty of the supporting evidence for the majority of recommendations was judged as low or very low, largely due to a lack of direct evidence for thoracic surgery. The panel made conditional recommendations for use of parenteral anticoagulation for VTE prevention, in combination with mechanical methods, over no prophylaxis for cancer patients undergoing anatomic lung resection or esophagectomy. Other key recommendations include: conditional recommendations for using parenteral anticoagulants over direct oral anticoagulants, with use of direct oral anticoagulants suggested only in the context of clinical trials; conditional recommendation for using extended prophylaxis for 28 to 35 days over in-hospital prophylaxis only for patients at moderate or high risk of thrombosis; and conditional recommendations for VTE screening in patients undergoing pneumonectomy and esophagectomy. Future research priorities include the role of preoperative thromboprophylaxis and the role of risk stratification to guide use of extended prophylaxis.
引用
- Shargall Y, Wiercioch W, Brunelli A, et al. Joint 2022 European Society of Thoracic Surgeons and The American Association for Thoracic Surgery guidelines for the prevention of cancer-associated venous thromboembolism in thoracic surgery. J Thorac Cardiovasc Surg. 2022. PMID: 36895083. doi:10.1016/j.jtcvs.2022.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。